Literature DB >> 26427910

Cerebral hemodynamics in orthostatic intolerance with normal head-up tilt test.

K J Shin1, S E Kim1, K M Park1, J Park1, S Y Ha1, S E Kim1, O-Y Kwon2.   

Abstract

OBJECTIVES: Orthostatic hypotension (OH) and postural orthostatic tachycardia syndrome (POTS) are well-known causes of orthostatic intolerance (OI). In addition, there are OI patients who are characterized by the symptoms of OI and lack of abnormal findings in head-up tilt (HUT) test. The aim of this study was to determine the cerebral hemodynamic changes in HUT test of OI patients with normal HUT (OINH).
MATERIALS AND METHODS: Two hundred and sixty-one OI patients and 50 healthy controls were enrolled in this study. All subjects underwent transcranial Doppler test while performing the HUT test. Forty-five patients had OH, 33 patients had POTS, and 183 patients had OINH. Blood pressures, heart rate, cerebral blood flow velocities (CBFVs), end-tidal carbon dioxide (ET-PCO2 ), cerebral critical closing pressure (CCP), cerebral perfusion pressure (CPP), and cerebral vascular resistance (CVR) were measured during HUT test. We compared the hemodynamic parameters of OINH with those of OH, POTS, and healthy controls.
RESULTS: Reduced CBFVs, CPP, and ET-PCO2 and elevated CCP were observed in the HUT test of all four groups. CVR was reduced in three OI patients. The drops in systolic CBFV, CPP, and CVR of OINH patients were greater than those of healthy controls. The changes in parameters in the HUT test of OINH group were not different from those of OH and POTS groups except prominent decrements of CPP and CVR in OH group.
CONCLUSION: Our findings suggest that OINH is true OI sharing the common pathomechanism of OH and POTS.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hemodynamic; orthostatic hypotension; orthostatic intolerance; postural orthostatic tachycardia syndrome; transcranial Doppler

Mesh:

Year:  2015        PMID: 26427910     DOI: 10.1111/ane.12516

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

Review 1.  Transcranial Doppler in autonomic testing: standards and clinical applications.

Authors:  Lucy Norcliffe-Kaufmann; Brahyan Galindo-Mendez; Ana-Lucia Garcia-Guarniz; Estibaliz Villarreal-Vitorica; Vera Novak
Journal:  Clin Auton Res       Date:  2017-08-18       Impact factor: 4.435

2.  Orthostatic intolerance in chronic fatigue syndrome.

Authors:  Richard Garner; James N Baraniuk
Journal:  J Transl Med       Date:  2019-06-03       Impact factor: 5.531

3.  Cerebral blood flow remains reduced after tilt testing in myalgic encephalomyelitis/chronic fatigue syndrome patients.

Authors:  C Linda M C van Campen; Peter C Rowe; Frans C Visser
Journal:  Clin Neurophysiol Pract       Date:  2021-09-23

4.  Cerebral Blood Flow Is Reduced in Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients During Mild Orthostatic Stress Testing: An Exploratory Study at 20 Degrees of Head-Up Tilt Testing.

Authors:  C Linda M C van Campen; Peter C Rowe; Frans C Visser
Journal:  Healthcare (Basel)       Date:  2020-06-13

5.  Monitoring of cerebral oximetry in patients with postural orthostatic tachycardia syndrome.

Authors:  Isabella Kharraziha; Hannes Holm; Erasmus Bachus; Olle Melander; Richard Sutton; Artur Fedorowski; Viktor Hamrefors
Journal:  Europace       Date:  2019-10-01       Impact factor: 5.214

6.  Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography.

Authors:  C Linda M C van Campen; Freek W A Verheugt; Peter C Rowe; Frans C Visser
Journal:  Clin Neurophysiol Pract       Date:  2020-02-08

7.  Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  C Linda M C van Campen; Peter C Rowe; Frans C Visser
Journal:  Medicina (Kaunas)       Date:  2021-12-24       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.